Daily Archives: September 23, 2016

Breakthrough Therapy Status, AdComms and Approvals

In recent years FDA has undertaken several means to facilitate the consideration of new drug applications by creating various mechanisms for expedited review for either new drugs or new indications for existing drugs. Prior to 2012, there had long been … Continue reading

Posted in Advisory Committee Prepapartion, FDA Policy | 1 Comment